晚期霍奇金淋巴瘤早期中期PET的基于结局的解读
HD18研究在新诊断晚期霍奇金淋巴瘤患者中,于2周期递增剂量eBEACOPP后行PET-2,按Deauville评分分析PET-2结果与基线特征及生存的关联。接受6周期标准eBEACOPP的722例患者中,DS4较DS1-3的PFS单因素HR为2.3(1.3-3.8;P=.002),OS单因素HR为2.6(1.0-6.6;P=.04)。作者推荐DS4作为PET-2阳性的截断值。
要点
- PET-2的DS4与接受eBEACOPP患者较差的PFS和OS相关。
- 6周期eBEACOPP后,DS1-2、DS3、DS4的3年PFS率分别为92.2%、95.9%、87.6%。
- 作者推荐DS4作为PET-2阳性的截断值。
核心结论
- PET-2时残留摄取高于肝脏(即DS4)是接受eBEACOPP upfront治疗患者生存结局的重要风险因素,作者推荐DS4作为PET-2阳性的截断值。
研究设计与样本
- HD18试验纳入新诊断晚期霍奇金淋巴瘤患者,于2周期递增剂量eBEACOPP后行PET-2,按Deauville评分视觉比较残留组织与参考区域,分析PET-2摄取与基线特征、PFS和OS的关联。
主要发现
- PET-2摄取与基线风险因素大纵隔肿块、结外病变和高国际预后评分相关(每项P<.0001)。
- 接受6周期eBEACOPP标准治疗的722例患者中,DS1-2、DS3、DS4的3年PFS率分别为92.2%、95.9%、87.6%。
- DS4 vs DS1-3的PFS单因素HR为2.3(1.3-3.8;P=.002),多因素分析中DS4是唯一保持显著的PFS因素。
- 3年OS率DS1-2为97.6%、DS3为99.0%、DS4为96.8%,DS4 vs DS1-3的单因素HR为2.6(1.0-6.6;P=.04)。
关键数值与推荐
- 作者推荐DS4作为PET-2阳性的截断值。
临床怎么用
- 作者推荐DS4作为PET-2阳性的截断值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The HD18 study for patients with newly diagnosed advanced-stage Hodgkin lymphoma (HL) used positron emission tomography (PET) after 2 cycles (PET-2) of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated doses (eBEACOPP) to guide further treatment. Here, we analyzed the impact of PET-2 results in the context of eBEACOPP according to the Deauville score (DS) in patients treated within the HD18 trial. Residual tissue was visually compared with reference regions according to DS. We analyzed the association between PET-2 uptake and baseline characteristics, progression-free survival (PFS), and overall survival (OS). One thousand five patients (52%) had DS1 or DS2, 471 (24%) had DS3, and 469 (24%) DS4. PET-2 uptake was associated with baseline risk factors large mediastinal mass, extranodal disease, and high International Prognostic Score (P < .0001 each). Among 722 patients receiving standard therapy with 6 cycles of eBEACOPP, 3-year PFS rates were 92.2%, 95.9%, and 87.6% with DS1-2, DS3, and DS4, respectively. Univariate hazard ratio (HR) for PFS in patients with DS4 vs DS1-3 was 2.3 (1.3-3.8; P = .002). DS4 was the only factor remaining significant for PFS in a multivariate analysis including the associated baseline risk factors. Three-year OS rates were 97.6% for DS1-2, 99.0% for DS3, and 96.8% for DS4, with a univariate HR for DS4 vs DS1-3 of 2.6 (1.0-6.6; P = .04). Residual uptake above that in the liver at PET-2 (ie, DS4) is an important risk factor regarding survival outcomes for patients treated with eBEACOPP upfront. We thus recommend DS4 as the cutoff value for PET-2 positivity. This trial was registered at www.clinicaltrials.gov as #NCT00515554.
引用
- Kobe C, Goergen H, Baues C, et al. Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma. Blood. 2018. PMID: 30166329. doi:10.1182/blood-2018-05-852129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。